Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Net Margin (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Net Margin for 16 consecutive years, with 248.18% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin changed N/A to 248.18% in Q3 2025 year-over-year; TTM through Sep 2025 was 114.59%, a 35064.0% increase, with the full-year FY2024 number at 88.01%, up 7428.0% from a year prior.
  • Net Margin was 248.18% for Q3 2025 at NovaBay Pharmaceuticals, down from 52.49% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 3.39% in Q1 2022 to a low of 449.26% in Q4 2023.
  • A 5-year average of 125.41% and a median of 94.11% in 2021 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -22401bps in 2023, then soared 39677bps in 2024.
  • NovaBay Pharmaceuticals' Net Margin stood at 20.19% in 2021, then plummeted by -1016bps to 225.25% in 2022, then tumbled by -99bps to 449.26% in 2023, then soared by 88bps to 52.49% in 2024, then plummeted by -373bps to 248.18% in 2025.
  • Per Business Quant, the three most recent readings for NBY's Net Margin are 248.18% (Q3 2025), 52.49% (Q4 2024), and 49.06% (Q2 2024).